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i. Summary 
Since its identification in the 1990s, the RNA interference (RNAi) pathway has proven 
extremely useful in elucidating the function of proteins in the context of cells and even 
whole organisms. In particular, this sequence-specific and powerful loss-of-function 
approach has greatly simplified the study of the role of host cell factors implicated in the 
life cycle of viruses. Here, we detail the RNAi method we have developed and used to 
specifically knock-down the expression of ezrin, an actin binding protein that was 
identified by yeast two-hybrid screening to interact with the Severe Acute Respiratory 
Syndrome Coronavirus (SARS-CoV) spike (S) protein. This method was used to study 
the role of ezrin, specifically during the entry stage of SARS-CoV infection. 
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1. Introduction 
The discovery of RNA interference (RNAi) represents a quantum leap in the fields of 
molecular and cellular biology [1,2]. RNAi technologies are powerful tools that are 
widely used to investigate the biological function of specific proteins either in vitro or in 
vivo. In particular, RNAi has successfully been used in virology to study the role of 
specific host proteins in the life cycle and replication of viruses. The introduction into 
cells of small interfering RNAs (siRNA), 20-25 nucleotide short double-stranded RNAs 
that are specific to target mRNA sequences and allow for sequence-specific 
degradation of the mRNA, is a relatively fast, simple and robust method to specifically 
down-regulate protein expression and study their function [3]. In our studies, siRNA has 
proven very useful to validate the functional relevance of cellular proteins that were 
identified by yeast two-hybrid screens as binding partners of influenza and coronavirus 
structural proteins [4,5]. We describe herein a method to efficiently knock-down protein 
expression of a cellular actin binding protein, ezrin, and measure the knock-down 
efficiency. This method was successfully used to investigate the role of ezrin during host 
cell entry and infection of the Severe Acute Respiratory Syndrome Coronavirus (SARS-
CoV) [5]. While the method described here is specific to the down regulation of ezrin 
expression, it can easily be modified and adapted to study the function of other cellular 
proteins during viral infection. The methodology described also forms the basis for 
larger scale experiments such as siRNA library screenings (see Note 1), which we have 
successfully established to study host cell factors involved in viral assembly and release 
[6]. 
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2. Materials 
2.1. siRNA components 
1. 1 × siRNA buffer : 60 mM KCl, 0.2 mM MgCl2, 6 mM HEPES, pH 7.5 (using 2 M KOH 
and a pH-meter). 
2.  20 µM ezrin-specific small interfering RNAs in 1 x siRNA buffer (Table 1 and see 
Notes 2, 3 and 4). 
3. 20 µM negative control non-targeting siRNA in 1 x siRNA buffer.   
4. DharmaFECT 1 transfection reagent (GE Dharmacon) or similar. 
 
2.2. Cell culture components 
1. HeLa-F5 cells (see Note 5). 
2. 96-well cell culture-treated plates (see Note 6). 
3. Phosphate buffer saline (PBS). 
4. Dulbecco’s Modified Eagle Medium (DMEM High Glucose GlutaMaxTM - Life 
Technologies) : 0.4 mM glycine, 3.972 mM L-alanyl-glutamine, 0.398 mM L-arginine 
hydrochloride, 0.153 mM L-cystine, 0.2 mM L-histidine hydrochloride-H2O, 0.802 mM L-
isoleucine, 0.802 mM L-leucine, 0.798 mM L-lysine hydrochloride, 0.201 mM L-
methionine, 0.4 mM L-phenylalanine, 0.4 mM L-serine, 0.798 mM L-threonine, 0.078 
mM L-tryptophan, 0.398 mM L-tyrosine disodium salt dihydrate, 0.803 mM L-valine, 
0.029 mM choline chloride, 0.008 mM D-calcium pantothenate, 0.009 mM folic acid, 
0.033 mM niacinamide, 0.019 mM pyridoxine hydrochloride, 0.001 mM riboflavin, 0.012 
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mM thiamine hydrochloride, 0.04 mM i-inositol, 1.802 mM CaCl2, 2.475 × 10
-4 mM 
Fe(NO3)3 9H2O, 0.814 mM MgSO4, 5.333 mM KCl, 44.048 mM NaHCO3, 110.345 mM 
NaCl, 0.906 mM NaH2PO4 H2O, 25 mM D-glucose, 0.04 mM phenol red, 1 mM sodium 
pyruvate. 
5. DMEM-C : DMEM supplemented with 10% fetal bovine serum (Life technologies), 
100 U/mL penicillin (Life Technologies), 100 µg/mL streptomycin (Life Technologies). 
Pass solution through a 0.22 µm filtration unit before use and store at +4˚C. 
6. DMEM-T : DMEM supplemented with 10% fetal bovine serum (Life technologies) 
(see Note 7). 
7. Polystyrene vials. 
 
2.3. Western blot components 
1. Lysis buffer : RLT buffer (Qiagen). Allows for isolation of proteins as well as nucleic 
acids. 
2. Protein sample loading buffer (4 × LDS sample buffer, Life technologies): 106 mM 
Tris HCl, 141 mM Tris Base, 2% lithium dodecyl sulfate (LDS), 10% glycerol, 0.51 mM 
EDTA, 0.22 mM SERVA blue G250, 0.175 mM phenol red.  
3. Sample reducing agent (10 x, Life technologies): 500 mM dithiothreitol (DTT). 
4. Polyacrylamide gel for protein electrophoresis: Novex Bis-Tris 4-12% gradient gel, 10 
wells. 
5. Gel running buffer (20 × NuPAGE MOPS SDS running buffer, Life technologies): 50 
mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA. 
6. Protein ladder: Novex Sharp pre-stained protein standard (Life technologies). 
 6 
7. Electrophoresis and blotting module: XCell SureLock Mini-Cell (Life technologies), or 
similar. 
8. Transfer buffer (20 × NuPAGE transfer buffer, Life technologies): 25 mM bicine, 25 
mM Bis-Tris (free base), 1 mM EDTA. 
9. Filter paper. 
10. Polyvinylidene fluoride (PVDF) membrane. 
11. Blotting sponge pads. 
12. Tris-buffer saline (10 × TBS):  200 mM Tris base, 1.5 M NaCl, pH to 7.6 with 12 N 
HCl (use a pH-meter). 
13.  TBST : TBS, 0.1% Tween-20 (see Note 8).  
14.  Blocking solution : 5% milk in TBST. 
15. Rabbit polyclonal anti-ezrin (generous gift from Dr. Monique Arpin, Institut Curie, 
France). 
16.  Mouse monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
17. Horse radish peroxidase (HRP) conjugated goat anti-rabbit. 
18.  HRP conjugated rabbit anti-mouse IgG. 
19. Enhanced chemiluminescence (ECL) compounds. 
20. Gel Doc system capable of reading chemiluminescent signals e.g. Bio-Rad Gel Doc 
XR system. Alternatively, membranes can be exposed on X-ray films. Exposure times 
may vary from a few seconds to several minutes. 
21. ImageJ or similar software for band quantification. 
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3. Methods 
The following procedures should be performed in a Class II biosafety cabinet, unless 
otherwise noted. The siRNA transfection method below describes the procedure for 
transfecting a specific set of siRNAs (ezrin-targeting or non-targeting siRNAs). As 
siRNAs are fragile, they should be kept on ice as much as possible. Perform each 
siRNA treatment condition in triplicates. In our experiments, because cells that undergo 
siRNA treatment will subsequently be virally infected, care should be taken at all steps 
to ensure the cells being treated are in the best condition and viability assessed as 
much as possible (see Note 9). 
 
3.1. siRNA transfection (for each type of siRNA) 
1. Seed 3.6 x 103 cells per well of a 96-well plate. Incubate at 37 ˚C for 16-18 hours. 
2. Dilute stock siRNA solution 1/10, to 2 µM, with 1 × siRNA buffer. 
3. Mix 2 µM siRNA solution with serum-free DMEM to obtain a 1 µM solution using a 1:1 
ratio. For mock siRNA condition, replace siRNA solution by DMEM. 
4. Perform gentle up-down pipetting and incubate tube at room temperature for 5 
minutes. 
5. Dilute to 1/50 DharmaFECT 1 transfection reagent with DMEM in a polysterene vial. 
6. Perform gentle up-down pipetting and incubate tube at room temperature for 5 
minutes. 
7. Mix siRNA-DMEM solution with transfection reagent-DMEM solution using a 1:1 ratio, 
by adding the transfection reagent-DMEM solution to the siRNA DMEM solution. 
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8. Incubate at room temperature for 20 minutes. 
9. Dilute siRNA-transfection reagent mix with DMEM-T using a 1/5 dilution. 
10. Aspirate culture medium from wells. 
11. Add 100 µl of transfection mix per well. 
12. Incubate at 37 ˚C cell culture incubator for 48 hours. 
13. Check for cytotoxicity or cell morphological changes routinely by observing 
transfected cells under microscope. 
14. Optional : Repeat siRNA transfection to increase knock-down efficiency and 
incubate for another 48 hours (see Note 10). Check for cytotoxicity or cell morphological 
changes under microscope (Figure 1).  
 
3.2. Measurement of siRNA knock-down efficiency 
A crucial step in any siRNA transfection experiment is to assess the level of knock-down 
of expression induced by such treatment. The section below describes how to evaluate 
siRNA knock-down by measuring the lowering of ezrin protein expression using a 
Western blot approach (see Note 11).  
 
1. Lyse cells by adding 100 µl lysis buffer per well (see Note 12), and incubate plate at 
room temperature for 15 minutes. Perform gentle up down pipetting to ensure lysis is 
complete. 
2. Add 40 µl 4 × Loading buffer, 16 µl 10 × DTT and 4 µl H2O to each sample. 
3. Boil samples at 95 ˚C for 5 minutes. 
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4. Cool samples down on ice and perform a quick centrifugation to bring down 
condensate. At this point, samples can be run through a gel or stored at -20 ˚C for later 
analysis. 
5. Place the pre-cast Bis-Tris polyacrylamide gel in electrophoresis module (see Note 
13).  
6. Fill inner and outer compartments of electrophoresis module with the 1 × running 
buffer. 
7. Load 10 µl of molecular weight standard ladder and load 10 µl of samples in each 
lanes. 
8. Run electrophoresis using following settings : 200 V with constant voltage for 45-60 
minutes. 
9. Cut out Whatman paper and PVDF membrane to the gel dimensions. 
10. Dehydrate PVDF membrane in 100% ethanol for 1 minute. 
11. Rehydrate membrane in H2O for 5 minutes, and then incubate it in 1 × transfer 
buffer for 5 minutes. 
12. Soak blotting paper and sponge pads in 1 × transfer buffer for at least 5 minutes. 
13. Remove gel from plastic encasing and immerse gel in 1 × transfer buffer. 
14. Prepare transfer stack by layering (from bottom to top) 2 blotting sponge pads, 3 
blotting paper cutouts, gel, PVDF membrane. Gently roll out bubbles with roller e.g. a 
small pipette. Continue stack by adding 3 blotting paper cutouts and 2 sponge pads. 
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15. Place the stack in transfer module and perform transfer inside electrophoresis 
module filled with 1 × transfer buffer using the following settings : 170 mA constant 
current for 1-2 hours. 
16. Remove membrane from stack and place in TBST solution. 
17. Block membrane in blocking solution for 1 hour at room temperature. 
18. Prepare primary antibody solutions by diluting them in blocking solution : rabbit 
polyclonal anti-ezrin: 1/1000; goat anti-GAPDH 1/10,000. 
19. Cut a straight line on the membrane at 50 kDa marker. Incubate top part with anti-
ezrin antibody solution and the bottom part with anti-GAPDH antibody solution for 1 
hour each. 
20. Wash membranes 3 times 10 minutes in TBST. 
21. Prepare secondary antibodies by diluting them in blocking solution : HRP goat anti-
rabbit IgG 1/1000; HRP rabbit anti-goat IgG 1/1000. 
22. Incubate membranes in the corresponding secondary antibody solutions for 45 
minutes. 
23. Wash membranes 3 times 10 minutes in TBST. 
24. Mix ECL solutions using a 1:1 ratio and add 1-2 mL of mixed solution to membrane 
surface. 
25. Incubate for 1 minute, remove excess moisture and perform band detection using 
gel doc or film and developer (Figure 2). 
26. Perform band quantification analysis using Gel Analysis module of ImageJ or similar 
software. For each lane, the GAPDH (housekeeping protein) band serves as a loading 
 11 
control. Normalise ezrin band relative intensity (Iezrin) to GAPDH band relative intensity 
(IGAPDH): 
𝐼𝑒𝑧𝑟𝑖𝑛
𝐼𝐺𝐴𝑃𝐷𝐻
 
27. The percentage of ezrin protein expression knock-down by siRNA treatment, 
compared to non-targeting control is calculated by the following equation (KD, 
expressed in %, table 2) : 
𝐾𝐷 =
[
 
 
 
 
1 −
(
𝐼𝑒𝑧𝑟𝑖𝑛
𝐼𝐺𝐴𝑃𝐷𝐻
)
𝑒𝑧𝑟𝑖𝑛 
𝑠𝑖𝑅𝑁𝐴 𝑙𝑎𝑛𝑒 
(
𝐼𝑒𝑧𝑟𝑖𝑛
𝐼𝐺𝐴𝑃𝐷𝐻
)
𝑛𝑜𝑛−𝑡𝑎𝑟𝑔𝑒𝑡𝑖𝑛𝑔 
𝑠𝑖𝑅𝑁𝐴 𝑙𝑎𝑛𝑒 ]
 
 
 
 
×  100 
 
 
4. Notes 
1. The method described here focuses on knocking-down expression of a single cellular 
gene, ezrin, to uncover its functional role in SARS-CoV infection. This methodology 
forms the basis for larger-scale functional analyses as it can easily be scaled up to 
perform siRNA-based functional screen studies to identify host genes involved in the 
replicative cycle of viruses. Such siRNA-based screening approach has been 
successfully developed in our lab using a siRNA library screen of 122 cellular genes 
involved in membrane trafficking to reveal host factors that are functionally implicated in 
dengue virus assembly and release [6]. 
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2. siRNAs should be handled with special care. RNA molecules are prone to 
degradation by RNases. Gloves and RNAse-free pipette tips should be used. Tubes 
containing siRNAs should be kept on ice as much as possible. Store siRNAs at -20˚C 
and aliquot stock solutions to avoid multiple freeze-thaw cycles.  
3. The ezrin siRNAs used here are in the form of an equimolar mix of four siRNA 
duplexes. This allows for robust knock-down of expression because it increases the 
odds of binding to target mRNA sequence and silencing to ensue.  It is important to note 
however that individual siRNAs can also be used to silence specific mRNA expression. 
This alternative approach has the advantage to minimize potential off-target effects of 
pooled siRNA mixes. We have validated the use of individual siRNA treatment for ezrin 
silencing, and successfully used an individual siRNA duplex to silence annexin A6 to 
investigate its functional role in influenza virus infection [4]. Another consideration when 
performing siRNA studies is the potential for functional redundancies found in families of 
closely related proteins. In another dengue virus study from our lab, we have found that, 
while individually silencing the closely-related small GTPases Arf4 or Arf5 had minimal 
effect on dengue virus secretion from cells, combined silencing of these two GTPases 
allowed for marked decrease in secretion [7]. 
4.  siRNAs are used at a final concentration of 100 nM for transfection of cells. This 
concentration was determined to be the best compromise between siRNA knock-down 
efficiency and cell viability by prior optimization experiments that tested increasing 
concentrations of siRNAs. As optimal siRNA concentration varies depending on cell 
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type used and target gene, we recommend performing such optimization during the 
setting up of any siRNA assay. 
5.  The choice of cell lines for conducting siRNA transfections is an important step 
during the setting-up and optimization of the assay. HeLa-F5 cells were chosen in our 
experiments because they robustly express ACE-2, the SARS-CoV receptor and was 
shown previously to be susceptible to SARS-CoV S-mediated viral entry. Furthermore, 
we have conducted preliminary siRNA transfection on a panel of cell lines, which 
included HeLa-F5, and found that those cells could be efficiently transfected, with ezrin 
protein expression levels significantly reduced after siRNA treatment. 
6. In the experiment described herein, siRNA transfections and subsequent assays 
were performed in 96-well cell culture-treated plates. Depending on the experiment 
planned using the siRNA-treated cells, the format can be adapted to larger culture 
plates. In that case, the number of cells and volumes of reagents used will have to be 
proportionally scaled up. 
7. Avoiding addition of penicillin/streptomycin to the transfection medium (DMEM-T) is 
important because lipid-based transfection reagents, such as DharmaFECT 1 increases 
the permeability of the cell plasma membrane. If present in the transfection medium, 
there is a greater risk for cellular uptake of the antibiotics with potentially higher 
cytotoxicity and lower transfection efficiency. 
8. Tween-20 is a viscous solution. To ensure that the correct volume of Tween-20 is 
added to the TBS buffer, cut a 1000 µL pipette tip, gently aspirate Tween-20 and add to 
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TBS buffer. Pipette up-down gently and eject tip in buffer. Add stir bar and let solution 
stir with pipette tip for ~30 minutes, or until Tween-20 has completely dissolved. 
9. The siRNA transfection procedure involves many steps of aspiration of supernatants 
and addition of solutions on cells. To avoid detaching cells, care should be taken to 
avoid letting the cells be without medium for more than a few minutes. Also, when 
adding new medium, solutions should not be pipetted directly on cells, but on the walls 
of the wells. Media should be pre-warmed at 37˚C as much as possible, as cold 
solutions can easily detach cells. We performed routine cell viability assays to 
determine the cytotoxic effects of siRNA treatments, using Trypan blue exclusion assay 
after treatments.  
10. The repeat of the siRNA transfection step 48 hours after the first one depends on 
several parameters including the efficiency of knock-down after 48 hours, the turn-over 
of the targeted mRNA, or the half-life of the protein product. We have observed through 
a series of tests that the optimal conditions for the knock-down of ezrin was to perform 
two successive siRNA transfections, 48 hours apart.  
11. If antibodies for the protein of interest are unavailable, an alternative would be to 
perform a quantitative RT-PCR assay, using specific primers, to measure levels of 
corresponding messenger RNAs.  
12. After HeLa-F5 cells have undergone two successive siRNA transfections, the siRNA 
efficiency control plate is used to assess the quality of knock-down. Analysis of ezrin or 
GAPDH (house-keeping protein) protein content from one well of a 96 well plate is 
sufficient for detection by Western blot. 
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13. An alternative to the pre-cast Bis-Tris polyacrylamide gel electrophoresis (PAGE) 
system is the use of gels prepared in the laboratory using gel casters. This allows 
customizing gels to the most appropriate percentage of polyacrylamide for the protein to 
be analyzed. 8 to 12 % polyacrylamide separating gel (8, 10 or 12 % Acrylamide/Bis-
Acrylamide, 400 mM Tris HCl pH 8.8, 0.1 % SDS, 0.04 % ammonium persulfate (APS), 
0.07 % tetramethylethylenediamine (TEMED) added last, ddH2O) and 4 % 
polyacrylamide stacking gel (4 % Acrylamide/Bis-Acrylamide, 100 mM Tris HCl pH 6.8, 
0.1 % SDS, 0.06 % APS, 0.1 % TEMED added last, ddH2O) are commonly used.   
Laboratory-made running, loading and transfer buffers can also be prepared in the 
laboratory following standard Western blotting procedures.  
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Figure legends 
Figure 1. Cell morphology and density after siRNA transfections. 3.6 × 103 HeLa-
F5 cells were seeded in wells of a 96-well plate. The cells were then transfected with 
either non-targeting or ezrin-targeting siRNAs and incubated at 37 ˚C cell culture 
incubator for 48 hours. A second round of siRNA transfection was then performed and 
cells were incubated at 37 ˚C cell culture incubator for 48 hours. The cells were then 
observed under an inverted microscope using at 10 × objective and pictures of 
representative fields were taken. 
 
Figure 2. Assessment of ezrin protein expression knock-down induced by siRNA 
transfections. 3.6 × 103 HeLa-F5 cells were seeded in wells of a 96-well plate. The 
cells were transfected twice with non-targeting or ezrin-targeting siRNAs. For each 
condition, cells from one well were lysed and analyzed for ezrin and GAPDH 
housekeeping protein content by Western blot. The Western blot shown here displays 
three independent replicates for either non targeting or ezrin targeting siRNAs. 
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Tables 
Table 1. Forward sequences of siRNA used to knock-down ezrin. 
siRNA duplex Forward sequence (5'-3') Nucleotides 
1 GCUCAAAGAUAAUGCUAUGUU 21 
2 GGCAACAGCUGGAAACAGAUU 21 
3 CAAGAAGGCACCUGACUUUUU 21 
4 GAUCAGGUGGUAAAGACUAUU 21 
 
The sequences were designed based on the VIL2 or EZR gene sequence (NCBI 
accession number: NM_003379). The siRNA duplexes were used in transfections as an 
equimolar pooled mix. 
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Table 2. Knock-down analysis after siRNA transfection. 
  
Band 
intensity 
Knock-
down 
(%) 
Average 
knock-
down 
(%) 
Standard 
deviation 
(%) 
ezrin siRNA 
1 
Iezrin 254 
95.2% 
95.0% 1.2% 
IGAPDH 26,582 
non targeting 
siRNA 1 
Iezrin 4,602 
IGAPDH 23,119 
ezrin siRNA 
2 
Iezrin 265 
93.7% 
IGAPDH 22,011 
non targeting 
siRNA 2 
Iezrin 4,433 
IGAPDH 23,098 
ezrin siRNA 
3 
Iezrin 196 
96.0% IGAPDH 18,857 
non targeting 
siRNA 3 
Iezrin 5,042 
IGAPDH 19,165 
 
HeLa-F5 cells were transfected twice with non-targeting or ezrin-targeting siRNAs and 
protein content was assessed by Western blot. Western blot band intensities were 
analyzed with ImageJ and the knock-down efficiency (KD) was calculated. 
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